A Randomized, Double-blind, Placebo-controlled, Dose Escalating Study to Examine the Safety, Tolerability and Pharmacokinetic Profile of Single Oral Doses of SLx-2119 in Healthy Male Subjects
Latest Information Update: 29 Jun 2023
At a glance
- Drugs Belumosudil (Primary)
- Indications Autoimmune disorders; Cancer; Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Kadmon Holdings
- 19 Nov 2013 Status changed from recruiting to completed, based on information in an article published in Annals of Clinical and Translational Neurology.
- 27 Feb 2012 Dosing of subjects has been initiated, according to a Kadmon Corporation media release
- 27 Feb 2012 New trial record